Navigation Links
Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Affymax, Inc.
Date:3/1/2013

WAYNE, Pa., March 1, 2013 /PRNewswire/ -- Ryan & Maniskas, LLP (www.rmclasslaw.com/cases/affy) announces that a class action lawsuit has been filed in the United States District Court for the United States District Court for the Northern District of California on behalf of purchasers of Affymax, Inc. ("Affymax") (NASDAQ: AFFY) common stock during the period between December 8, 2011 and February 22, 2013 (the "Class Period").

(Logo: http://photos.prnewswire.com/prnh/20121112/MM11729LOGO )

For more information regarding this class action suit, please contact Ryan & Maniskas, LLP ( Richard A. Maniskas, Esquire ) toll-free at (877) 316-3218 or by email at rmaniskas@rmclasslaw.com or visit: www.rmclasslaw.com/cases/affy.The complaint alleges that during the Class Period, defendants issued materially false and misleading statements regarding the Company's business practices and financial results. Specifically, the complaint alleges that defendants failed to disclose that 2% of patients who were administered Omontys experienced hypersensitivity reactions resulting in anaphylaxis, a serious and life-threatening allergic reaction, a third of which needed medical intervention – and that 0.02% of those administered the drug experienced fatal anaphylaxis reactions. As a result of these false statements, the Complaint alleges that Affymax stock traded at artificially inflated prices during the Class Period, reaching a high of $27.74 per share in intraday trading on October 17, 2012.

Then, on February 23, 2013, Affymax and Takeda announced that the FDA was requiring a total recall of the drug due to reports of anaphylaxis, with the FDA calling it a "serious and life-threatening" allergic reaction in the agency's statement. "Serious and fatal" hypersensitivity reactions had been reported in some patients within 30 minutes of receiving their first doses of the drug by intravenous injection, the FDA said in its statement. On this news, the price of Affymax stock declined by more than 85%, closing at $2.42 per share, down $14.10 per share from the prior night's close, on unusually high trading volume.

If you are a member of the class, you may, no later than April 29, 2013, request that the Court appoint you as lead plaintiff of the class.  A lead plaintiff is a representative party that acts on behalf of other class members in directing the litigation.  In order to be appointed lead plaintiff, the Court must determine that the class member's claim is typical of the claims of other class members, and that the class member will adequately represent the class.  Under certain circumstances, one or more class members may together serve as "lead plaintiff."  Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff.  You may retain Ryan & Maniskas, LLP or other counsel of your choice, to serve as your counsel in this action.

For more information about the case or to participate online, please visit: www.rmclasslaw.com/cases/affy or contact Richard A. Maniskas, Esquire toll-free at (877) 316-3218, or by e-mail at rmaniskas@rmclasslaw.com.  For more information about class action cases in general or to learn more about Ryan & Maniskas, LLP, please visit our website: www.rmclasslaw.com.

Ryan & Maniskas, LLP is a national shareholder litigation firm.  Ryan & Maniskas, LLP is devoted to protecting the interests of individual and institutional investors in shareholder actions in state and federal courts nationwide.CONTACT:Ryan & Maniskas, LLPRichard A. Maniskas, Esquire995 Old Eagle School Rd., Suite 311Wayne, PA 19087484-588-5516877-316-3218www.rmclasslaw.com/cases/affy  rmaniskas@rmclasslaw.com


'/>"/>
SOURCE Ryan & Maniskas, LLP
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. On-Demand Reports on Partnering Terms in Healthcare & Pharma Sectors: New Market Research at ReportsnReports.com
2. Aethlon Medical (AEMD) Note: Multiple Shots on Goal - A Therapeutic Strategy to Address Infectious Disease & Cancer
3. Animas Development of a First-Generation Closed Loop Insulin Delivery System Progresses With Data Presented at the Advanced Technologies & Treatments for Diabetes (ATTD) Conference
4. Orexigen Therapeutics Announces Webcast of Upcoming Presentation at the Cowen & Co. Annual Health Care Conference
5. Collegium Pharmaceuticals CEO to Present at the Cowen & Company 33rd Annual Health Care Conference in Boston on March 6, 2013
6. BiOptix to highlight new carbonic anhydrase data at IBCs Biopharmaceutical Development & Production Week
7. Cadence Pharmaceuticals CEO Ted Schroeder To Present At The Cowen & Company 33rd Annual Health Care Conference In Boston On March 5, 2013
8. Searcy Denney Scarola Barnhart & Shipley Attorney Appointed to Plaintiffs Steering Committee for Stryker Hip Implant Litigation
9. Frost & Sullivan Recognizes KAERs Game-Changing Innovating Aerosol Drug Delivery Methods for High-Dose Respiratory Disease Therapeutics
10. Gliknik Adds Incyte President & CEO Paul A. Friedman to its Board of Directors
11. Frost & Sullivan Recognizes GenePOCs Growth Backed by Strong Leadership and Technology Excellence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... 2016 Global  urinalysis market ... by 2022, according to a new report by ... http://photos.prnewswire.com/prnh/20150105/723757 ) , Automation ... and accuracy delivered by the new generation urinalysis ... urinalysis instruments and consumables. For instance, the automatic ...
(Date:4/26/2016)... Diplomat Pharmacy, Inc. (NYSE: DPLO) is pleased ... Pharm D., to Vice President of Education and Quality. ... will continue to lead and oversee Diplomat University, an ... and training to Diplomat employees and external professionals on ... also houses the quality assurance department, which focuses on ...
(Date:4/26/2016)... -- Research and Markets has announced the ... report to their offering.      (Logo: ... market is projected to grow at a CAGR of ... is a technique that involves measurement and analysis of ... changes in biochemical pathways. The aim of performing these ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... 2016 , ... Regenerative Medicine Solutions (RMS) scored 94.8124 out of ... them second place for Tampa’s Best Places to Work. They were ranked in the ... great accomplishment for our team,” says RMS Human Resources Manager Irene Miller. “We work ...
(Date:4/29/2016)... ... 29, 2016 , ... The infertility specialists at HRC Fertility/Orange County (HRC/OC) -- ... A. Potter -- are proud of the recent release of their 2014 in vitro ... SART published the latest verified data for 375 U.S. member clinics. *Preliminary data ...
(Date:4/29/2016)... ... April 29, 2016 , ... Natren, Inc. recently sent representatives ... Petbiotics ™, as they fondly call them. As animal lovers, they were ... their non-profit organizations. Animal rescues across the nation face huge hurdles rescuing animals ...
(Date:4/29/2016)... ... April 29, 2016 , ... HEALTHCAREfirst , the ... services, and Deyta Analytics, recently announced the recipients of the fourth annual Hospice ... as measured from the caregiver’s point of view. The official list of recipients ...
(Date:4/29/2016)... , ... April 29, 2016 , ... ... study detailing the company’s use of Microsoft Dynamics GP for one their long-term ... a solution that integrated Dynamics GP with key clinical management systems, and delivered ...
Breaking Medicine News(10 mins):